IP Verse

Astrazeneca Ab opposition analysis

COMPANY ANALYSIS

Latest patents of Astrazeneca Ab opposed by its competitors

Patent:
EP3045466
Grant Date:
Oct 16, 2024
Title:
(2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Oppositions:
1
Patent:
EP4114465
Grant Date:
Aug 30, 2023
Title:
Anti-Ifnar1 Dosing Regime For Subcutaneous Injection
Oppositions:
1
Patent:
EP2508188
Grant Date:
May 10, 2023
Title:
Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate
Oppositions:
5
Patent:
EP3769781
Grant Date:
Apr 19, 2023
Title:
Stable Anti-Ifnar1 Formulation
Oppositions:
1
Patent:
EP2785349
Grant Date:
Nov 9, 2022
Title:
Combination Treatment Of Cancer
Oppositions:
1
Patent:
EP3142661
Grant Date:
Oct 6, 2021
Title:
Method For Suppressing Glucagon Secretion Of An Sglt2 Inhibitor
Oppositions:
1
Patent:
EP2139494
Grant Date:
Mar 11, 2020
Title:
Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate
Oppositions:
6
Patent:
EP3363807
Grant Date:
Nov 13, 2019
Title:
Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Oppositions:
1
Patent:
EP2498759
Grant Date:
Aug 1, 2018
Title:
Immediate Release Tablet Formulations
Oppositions:
4
Patent:
EP2498758
Grant Date:
Jul 25, 2018
Title:
Bilayer Tablet Formulations
Oppositions:
1

Competitors of Astrazeneca Ab

GENERICS (U.K.) LIMITED

GALENICUM HEALTH S.L.U.

GEDEON RICHTER PLC.

Want to track Astrazeneca Ab?

Feel free to send us a message here and we will get back to you